Literature DB >> 9288436

A possible new treatment approach to obsessive-compulsive disorder.

L Warneke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288436     DOI: 10.1177/070674379704200624

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


× No keyword cloud information.
  6 in total

1.  Substance use disorders in individuals with body dysmorphic disorder.

Authors:  Jon E Grant; William Menard; Maria E Pagano; Christina Fay; Katharine A Phillips
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

2.  Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.

Authors:  M Olga Rojas-Corrales; Juan Gibert-Rahola; Juan A Mico
Journal:  Psychopharmacology (Berl)       Date:  2006-11-11       Impact factor: 4.530

3.  Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder.

Authors:  Malcolm B Liddell; Victor Aziz; Patrick Briggs; Nimalee Kanakkehewa; Omar Rawi
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

Review 4.  The significance of the concept of obsessive-compulsive spectrum disorder to the treatment of chronic nonmalignant pain.

Authors:  O Joseph Bienvenu; Paul A Cannistraro
Journal:  Curr Pain Headache Rep       Date:  2002-02

5.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

Review 6.  Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Antonio Del Casale; Serena Sorice; Alessio Padovano; Maurizio Simmaco; Stefano Ferracuti; Dorian A Lamis; Chiara Rapinesi; Gabriele Sani; Paolo Girardi; Georgios D Kotzalidis; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.